Adiponectin, leptin, and resistin are the most well-studied adipokines and play important roles in the regulation of glucose metabolism, subclinical inflammation, and cardiovascular homeostasis. Accordingly, measurement of adipokine levels might be useful in cardiovascular risk stratification. Moreover, the study of single-nucleotide polymorphisms of genes that encode these adipokines might also represent a valuable predictive tool in cardiovascular disease prevention strategies.
Aims
To summarize the biologic role of the adipokines adiponectin, leptin, and resistin and the prognostic value of their serum levels regarding the occurrence and outcome of ischemic stroke. We also discuss the relationship of single-nucleotide polymorphisms of the adiponectin, leptin genes, and the −420C > G polymorphism of resistin gene with stroke risk.
Summary of review
Several studies in the general population evaluated the association between these adipokines and stroke risk, yielding conflicting results. There are more limited data regarding the effect of these adipokines on stroke severity and outcome. A small number of studies also assessed the predictive role of single-nucleotide polymorphisms of the adiponectin, leptin, and resistin genes regarding stroke risk, but the findings were also controversial.
Conclusions
It is unclear whether adiponectin, leptin, and resistin levels or the single-nucleotide polymorphisms of their encoding genes are independently associated with stroke risk. However, given the role of these adipokines in the pathogenesis of atherosclerosis, larger prospective studies, both in the general population and in patients with a history of stroke, are needed to determine whether the measurement of serum levels of these adipokines or the evaluation of single-nucleotide polymorphisms in their encoding genes could improve stroke risk prediction. If this relationship is proven, therapeutic interventions targeting adipokine levels might represent a novel approach to reduce stroke-related mortality and disability.
MozaffarianDBenjaminEJGoAS. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation2015; 131: e29–e322.
2.
KernanWNOvbiageleBBlackHR. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the Αmerican Heart Association/Αmerican Stroke Association. Stroke2014; 45: 2160–2236.
3.
PruggerCLucGHaasB. Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. Arterioscler Thromb Vasc Biol2013; 33: 659–666.
4.
GiannopoulosSKosmidouMHatzitoliosAISavopoulosCGZiakasAKaramouzisM. Measurements of endothelin-1, C-reactive protein and fibrinogen plasma levels in patients with acute ischemic stroke. Neurol Res2008; 30: 727–730.
5.
WhiteleyWChongWLSenguptaASandercockP. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke2009; 40: e380–e389.
6.
KönigIRZieglerABluhmkiE. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke2008; 39: 1821–1826.
7.
LiFYChengKKLamKSVanhouttePMXuA. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol (Oxf)2011; 203: 167–180.
BlüherMMantzorosCS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism2015; 64: 131–145.
10.
PruggerCLucGHaasB. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol2012; 71: 478–486.
11.
AthyrosVGTziomalosKKaragiannisAAnagnostisPMikhailidisDP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?Curr Drug Targets2010; 11: 122–135.
12.
DingQWhiteSPLingCZhouW. Resistin and cardiovascular disease. Trends Cardiovasc Med2011; 21: 20–27.
13.
SavopoulosCMichalakisKApostolopoulouMMirasAHatzitoliosA. Adipokines and stroke: a review of the literature. Maturitas2011; 70: 322–327.
14.
LiuFHeZDengSZhangHLiNXuJ. Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population. Mol Biol Rep2011; 38: 1983–1988.
15.
TangHZhangZLiZKLinJFangDZ. Association of leptin receptor gene polymorphisms with genetic susceptibility to ischemic stroke. J Stroke Cerebrovasc Dis2015; 24: 2128–2133.
16.
ChiSLanCZhangS. Association of −394C>G and −420C>G polymorphisms in the RETN gene with T2DM and CHD and a new potential SNP might be exist in exon 3 of RETN gene in Chinese. Mol Cell Biochem2009; 330: 31–38.
17.
HaoGLiWGuoR. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis2013; 228: 29–35.
18.
KizerJRBenkeserDArnoldAM. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab2013; 98: 255–263.
19.
EfstathiouSPTsioulosDITsiakouAGGratsiasYEPefanisAVMountokalakisTD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke2005; 36: 1915–1919.
20.
BidulescuALiuJChenZ. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study. Front Public Health2013; 1: 16.
21.
SongHJOhSQuanS. Gender differences in adiponectin levels and body composition in older adults: Hallym aging study. BMC Geriatr2014; 14: 8.
22.
KizerJRArnoldAMStrotmeyerES. Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality. The Cardiovascular Health Study All Stars Study. J Gerontol A Biol Sci Med Sci2010; 65: 1208–1214.
23.
BidulescuALiuJHicksonDA. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. BMC Cardiovasc Disord2013; 13: 9.
24.
MorimotoYConroySMOllberdingNJ. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond)2014; 38: 1416–1422.
25.
AzradMGowerBAHunterGRNagyTR. Racial differences in adiponectin and leptin in healthy premenopausal women. Endocrine2013; 43: 586–592.
26.
KhanUIWangDSowersMR. Race-ethnic differences in adipokine levels: the Study of Women's Health Across the Nation (SWAN). Metabolism2012; 61: 1261–1269.
27.
MenteARazakFBlankenbergS. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care2010; 33: 1629–1634.
28.
MartinezCMPWaldmanSDoriaC. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int2013; 83: 487–494.
29.
LimCCTeoBWTaiES. Elevated serum leptin, adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in asian adults. PLoS One2015; 10: e0122009.
30.
HuiXLamKSVanhouttePMXuA. Adiponectin and cardiovascular health: an update. Br J Pharmacol2012; 165: 574–590.
31.
KuwashiroTAgoTKamouchiM. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke—Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism2014; 63: 1093–1103.
EnnsJETaylorCGZahradkaP. Variations in adipokine genes AdipoQ, Lep, and LepR are associated with risk for obesity-related metabolic disease: the modulatory role of gene-nutrient interactions. J Obes2011; 2011: 168659.
34.
LiuJButlerKRBuxbaumSGSungJHCampbellBWTaylorHA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxf)2010; 72: 32–37.
35.
BeltowskiJ. Leptin and atherosclerosis. Atherosclerosis2006; 189: 47–60.
36.
AvrahamYDavidiNLassriV. Leptin induces neuroprotection neurogenesis and angiogenesis after stroke. Curr Neurovasc Res2011; 8: 313–322.
37.
AvrahamYDayanMLassriV. Delayed leptin administration after stroke induces neurogenesis and angiogenesis. J Neurosci Res2013; 91: 187–195.
38.
PanWHsuchouHJayaramB. Leptin action on nonneuronal cells in the CNS: potential clinical applications. Ann N Y Acad Sci2012; 1264: 64–71.
39.
ParkHKAhimaRS. Resistin in rodents and humans. Diabetes Metab J2013; 378: 404–414.
40.
LauCHMuniandyS. Adiponectin and resistin gene polymorphisms in association with their respective adipokine levels. Ann Hum Genet2011; 75: 370–382.
41.
EfstathiouSPTsiakouAGTsioulosDI. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta2007; 378: 78–85.
42.
SchwartzDRLazarMA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab2011; 22: 259–265.
43.
StottDJWelshPRumleyA. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol2009; 38: 253–261.
44.
RajpathakSNKaplanRCWassertheil-SmollerS. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke2011; 42: 1813–1820.
45.
ArreguiMBuijsseBFritscheA. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke2014; 45: 10–17.
46.
WannametheeSGShaperAGWhincupPHLennonLSattarN. Adiposity, adipokines, and risk of incident stroke in older men. Stroke2013; 44: 3–8.
47.
SöderbergSStegmayrBStenlundH. Leptin, but not adiponectin, predicts stroke in males. J Intern Med2004; 256: 128–136.
48.
MatsumotoMIshikawaSKajiiE. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke2008; 39: 323–328.
49.
KhaliliPFlyvbjergAFrystykJ. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study. Diabetes Metab2010; 36: 137–143.
50.
OgorodnikovaADWassertheil-SmollerSMancusoP. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke2010; 41: 1376–1381.
51.
KanhaiDAKranendonkMEUiterwaalCSVan Der GraafYKappelleLJVisserenFL. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev2013; 14: 555–567.
52.
LindbergSMogelvangRPedersenSH. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol2013; 111: 1139–1145.
53.
GardenerHGoldbergRMendezAJ. Adiponectin and risk of vascular events in the Northern Manhattan study. Atherosclerosis2013; 226: 483–489.
54.
IsobeTSaitohSTakagiS. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol2005; 153: 91–98.
55.
KoharaKOchiMOkadaY. Clinical characteristics of high plasma adiponectin and high plasma leptin as risk factors for arterial stiffness and related end-organ damage. Atherosclerosis2014; 235: 424–429.
56.
KimBJLeeSHRyuWSKimCKYoonBW. Adipocytokines and ischemic stroke: differential associations between stroke subtypes. J Neurol Sci2012; 312: 117–122.
57.
PeraJDziedzicTSzczudlikASlowikA. Temporal changes of adiponectin plasma levels in patients with acute ischemic stroke. Neurol Res2013; 35: 988–991.
58.
BaranowskaBKochanowskiJGrudniakM. Decreased total serum adiponectin and its isoforms in women with acute ischemic stroke. Neuro Endocrinol Lett2011; 32: 711–715.
59.
KantorovaEChomovaMKurcaE. Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuro Endocrinol Lett2011; 32: 716–721.
60.
JaleelAAqilSJaleelSJaleelF. Adipocytokines in subjects with and without ischemic cerebrovascular disease. Acta Neurol Belg2010; 110: 234–238.
61.
SasakiMOtaniTKawakamiMIshikawaSE. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism2010; 59: 527–532.
62.
JaleelAAqilSJaleelFAhmadHRZuberiAAlamE. Adiponectin and infarction size in subjects with and without cerebrovascular disease. Neurosciences (Riyadh)2009; 14: 245–248.
63.
ChenMPTsaiJCChungFM. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol2005; 25: 821–826.
64.
MarousiSTheodorouGKarakantzaMPapathanasopoulosPEllulJ. Serum adiponectin acutely after an ischemic stroke: implications for a long-lasting, suppressed anti-inflammatory role. Acta Neurol Scand2010; 121: 277–284.
65.
NagasawaHYokotaCToyodaKItoAMinematsuK. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci2011; 304: 102–106.
66.
CohoonKPMazurMMcBaneRDKethaSAmmashNWysokinskiWE. The impact of gender and left atrial blood stasis on adiponectin levels in non-valvular atrial fibrillation. Int J Cardiol2015; 181: 207–212.
67.
MacheretFBartzTMDjousseL. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart2015; 101: 1368–1374.
68.
MiaoJShenLHTangYH. Overexpression of adiponectin improves neurobehavioral outcomes after focal cerebral ischemia in aged mice. CNS Neurosci Ther2013; 19: 969–977.
DrechslerCKraneVWinklerKDekkerFWWannerC. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int2009; 76: 567–575.
71.
MarousiSGTheodorouGLKarakantzaMZampakisPPapathanasopoulosPEllulJ. Acute post-stroke adiponectin in relation to stroke severity, progression and 6 month functional outcome. Neurol Res2010; 32: 841–844.
72.
SöderbergSStegmayrBAhlbeck-GladerCSlunga-BirganderLAhrénBOlssonT. High leptin levels are associated with stroke. Cerebrovasc Dis2003; 15: 63–69.
73.
JalilAAmirSMajeedRJalilF. Circulating leptin levels in elderly subjects with and without cerebrovasular disease. J Coll Physicians Surg Pak2010; 20: 350–351.
74.
MenzaghiCBacciSSalveminiL. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One2013; 8: e64729.
75.
WeikertCWestphalSBergerK. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab2008; 93: 2647–2653.
76.
KochanowskiJGrudniakMBaranowska-BikA. Resistin levels in women with ischemic stroke. Neuro Endocrinol Lett2012; 33: 603–607.
77.
NakashimaEWataraiATsukaharaT. Association of resistin polymorphism, its serum levels and prevalence of stroke in Japanese type 2 diabetic patients. J Diabetes Invest2010; 1: 154–158.
78.
BevanSMeidtnerKLorenzMSitzerMGrantPJMarkusHS. Adiponectin level as a consequence of genetic variation, but not leptin level or leptin: adiponectin ratio, is a risk factor for carotid intima-media thickness. Stroke2011; 42: 1510–1514.
79.
CheongMYBangOSChaMHParkYKKimSHKimYJ. Association of the adiponectin gene variations with risk of ischemic stroke in a Korean population. Yonsei Med J2011; 52: 20–25.
80.
PatelSFlyvbjergAKozakovaM. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J2008; 29: 386–393.
81.
TanimuraDShibataRIzawaH. Relation of a common variant of the adiponectin gene to serum adiponectin concentration and metabolic traits in an aged Japanese population. Eur J Hum Genet2011; 19: 262–269.
82.
WasselCLPankowJSJacobsDR JrSteffesMWLiNSchreinerPJ. Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) study. Obesity (Silver Spring)2010; 18: 2333–2338.
83.
CohenSSGammonMDNorthKE. ADIPOQ, ADIPOR1, and ADIPOR2 polymorphisms in relation to serum adiponectin levels and BMI in black and white women. Obesity (Silver Spring)2011; 19: 2053–2062.
84.
HeidIMHennemanPHicksA. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis2010; 208: 412–420.
85.
QiLLiTRimmE. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes2005; 54: 1607–1610.
86.
HegenerHHLeeIMCookNRRidkerPMZeeRY. Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke: a nested case-control study. Clin Chem2006; 52: 2021–2027.
87.
YamadaYKatoKOguriM. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med2008; 21: 801–808.
88.
NorataGDOngariMGarlaschelliK. Effect of the −420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med2007; 262: 104–112.
89.
UkkolaOKunnariAKesäniemiYA. Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors. Regul Pept2008; 149: 56–59.
90.
LauCHMuniandyS. Adiponectin and resistin gene polymorphisms in association with their respective adipokine levels. Ann Hum Genet2011; 75: 370–382.
91.
HivertMFManningAKMcAteerJB. Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes2009; 58: 750–756.
92.
MenzaghiCCocoASalveminiL. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab2006; 91: 2792–2795.
93.
El-ShalASPashaHFRashadNM. Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene2013; 515: 233–238.
94.
OsawaHTabaraYKawamotoR. Plasma resistin, associated with single nucleotide polymorphism −420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care2007; 30: 1501–1506.
95.
OsawaHOnumaHOchiM. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun2005; 335: 596–602.
96.
OsawaHYamadaKOnumaH. The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet2004; 75: 678–686.
97.
QasimANMetkusTSTadesseM. Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol (Oxf)2009; 70: 698–705.
98.
OnumaHTabaraYKawamuraR. A at single nucleotide polymorphism-358 is required for G at −420 to confer the highest plasma resistin in the general Japanese population. PLoS One2010; 5: e9718.
99.
TsukaharaTNakashimaEWataraiA. Polymorphism in resistin promoter region at −420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract2009; 84: 179–186.
100.
ChoYMYounBSChungSS. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia2004; 47: 559–565.
101.
TangNPWangLSYangL. A polymorphism in the resistin gene promoter is related to increased C-reactive protein levels in patients with coronary artery disease. Clin Chem Lab Med2007; 45: 1471–1475.
102.
TangNPWangLSYangL. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol (Oxf)2008; 68: 82–87.
103.
KunnariAUkkolaOKesäniemiYA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med2005; 22: 583–589.
104.
LinXJZhangYDGuanQSDiQShiJPLiuWG. Plasma resistin levels and single-nucleotide polymorphisms in resistin gene 5' flanking region in patients with stroke. Chin Med Sci J2007; 22: 27–32.
